May 2017: The Antibody Update

In the May Antibody Update, you can expect to find news of an enzyme inhibitor that increases the efficacy of anti-PD-1 Immunotherapy, the generation of induced pluripotent blood stem cells, and the rapid employment of the latest Ebola vaccine in the Democratic Republic of the Congo. Learn more at ProSci.

Problems with Immunotherapy

Immune system checkpoint inhibition may not always be the perfect way to target cancer. Why is it that some patients do not respond positively to certain immunotherapy treatments like Ipilimumab? This blog takes into account the immune system's convoluted nature to understand how immune checkpoint antibodies may not be the problem, and how personalized medicine could help.

A Brief  Introduction to PD-1 Antibodies and Immunotherapy

T-cell PD-1/PD-L1 immunotherapy is one of the newest frontiers of cancer treatment and is changing the industry. Learn more about immunotherapy and its method of action in this blog.

December 2015: The Antibody Update

This month's Antibody Update includes the highlights of the Antibody Engineering and Therapeutics conference, Jimmy Carter's cancer remission, and another cancer antibody designed to target CD-47.